My SciELO
Services on Demand
Journal
Article
Indicators
- Cited by SciELO
- Access statistics
Related links
- Cited by Google
- Similars in SciELO
- Similars in Google
Share
Archivos de la Sociedad Española de Oftalmología
Print version ISSN 0365-6691
Abstract
RAMIREZ-SORIA, M.P.; ESPANA-GREGORI, E.; AVINO-MARTINEZ, J. and PASTOR-PASCUAL, F.. Blepharitis related to Cetuximab treatment in an advanced colorectal cancer patient. Arch Soc Esp Oftalmol [online]. 2008, vol.83, n.11, pp.665-668. ISSN 0365-6691.
Case report: A 52-year-old woman with advanced colorectal cancer was referred to us for treatment of Cetuximab-related ocular side-effects. Discussion: Cetuximab is a monoclonal antibody that specifically blocks epidermal growth factor receptor activity. It has recently been approved to treat some tumors such as metastatic colorectal cancer and some ORL cancers. Tolerance to it seems to be better than that to the classic chemotherapeutic agents. However it has several side-effects. Cetuximab-related eyelid toxicity has been recently described, though the pathogenesis has not yet been clearly established.
Keywords : Colorectal cancer; monoclonal antibodies; epidermal growth factor receptor; blepharitis.